NIMA collaborates with Eurofins to promote new celiac disease genetic risk test

Easy, take-at-home test, identifies HLA genetic risk factors for celiac disease with >99% accuracy

NIMA Partners, the makers of Gluten Sensor and Gluten Capsules for the detection of gluten in food particles, have entered into an exclusive partnership with Clinical Enterprise, Inc. (empowerDX- a subsidiary of the Eurofins Group) to cross-promote a new, revolutionary, at-home Celiac Risk Gene Test.

The test, from empowerDX, measures three HLA gene markers (HLA-DQ2 + HLA-DQ8 + DQA1*05) using two simple mouth swabs. It’s hoped that the test will help the estimated 1.4 million americans who have celiac disease – but don’t know it – take the first step towards treatment.

Celiac disease is an autoimmune genetic condition where the body’s immune system attacks the small intestine when gluten is consumed. Foods that contain gluten include breads, pastas, crackers, baked goods, many grains, and several beverages and processed items.

More than 99% of people who develop celiac disease carry one of the genetic variants identified by empowerDX’s new test. Symptoms can range from abdominal issues and joint pain to brain fog, depressed mood, and concentration issues. If left untreated, celiac disease can lead to serious health complications including heart disease, intestinal cancers, and fertility issues.

Read Previous

Fujitsu and Phytocontrol team up for new service to contribute to global food safety

Read Next

Lallemand Health Solutions supports innovative French Gut Project

Leave a Reply